Intra-Cellular Therapies saw its share price climb 86.9% to close at a new peak of $48.79 on Sept. 16 after the company reported that ITI-007 showed a potentially differentiated safety profile relative to approved antipsychotic drugs in the first of two Phase III schizophrenia clinical trials.
New York-based Intra-Cellular is pursuing a first-line indication for the treatment of schizophrenia with ITI-007, which combines serotonin 5-HT2A receptor...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
